Investments

Why Are Investors Increasing Their Holdings in Sutro Biopharma?
Management & Regulatory Why Are Investors Increasing Their Holdings in Sutro Biopharma?

Sutro Biopharma, Inc., a clinical-stage oncology company, has garnered significant attention from the investment community. Institutional investors like Susquehanna Fundamental Investments LLC recently bolstered their holdings by acquiring 126,459 shares valued at approximately $714,000 during the

Veranova Invests $30M in Devens Facility to Expand ADC Capabilities
Management & Regulatory Veranova Invests $30M in Devens Facility to Expand ADC Capabilities

In a significant move within the pharmaceutical manufacturing industry, Veranova has announced a substantial $30 million investment to enhance its Devens, Massachusetts facility. This strategic expansion is designed to bolster Veranova’s capabilities in developing and manufacturing antibody-drug

How Has Merck's €180M Boost Transformed Its German Hub?
Management & Regulatory How Has Merck's €180M Boost Transformed Its German Hub?

In a move that reaffirms its position as a powerhouse in the life sciences sector, Merck has made a resounding statement with a substantial €180 million investment to expand its distribution center in Schnelldorf, Germany. This ambitious project has nearly doubled the existing facility's size by an

Is Immunology the Next Frontier for Biopharma Giants?
Research & Development Is Immunology the Next Frontier for Biopharma Giants?

The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups

Can-Fite BioPharma Ratings Split Amid Financial Struggles
Management & Regulatory Can-Fite BioPharma Ratings Split Amid Financial Struggles

In the dynamic realm of biopharmaceutical investments, the diverging analyst ratings for Can-Fite BioPharma (NYSE: CANF) underscore the complex calculus of betting on drug development firms. The stock analysis firm StockNews.com has planted its flag with a "hold" rating, signaling a cautious stance

UD SABRE Center Boosts Biopharma with $45M Funding
Management & Regulatory UD SABRE Center Boosts Biopharma with $45M Funding

The University of Delaware is making major strides in the biopharma sector by launching the new SABRE Center. Backed by $45 million in federal funding, including $10 million from the American Rescue Plan, this 90,000-square-foot hub is set to propel the university into a leader in biopharmaceutical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later